Healthcare & Power
NUCLIDIUM and NorthStar say NorthStar will produce copper-67 and manufacture radiopharmaceuticals for NUCLIDIUM’s programs. No terms, volumes or capacity figures were disclosed, and the therapies remain investigational with no efficacy results reported.
Molecular Medicine
JAMA-published REVEAL results give peer-reviewed accuracy figures for an investigational amyloid tracer, but the single-arm design lacks head-to-head comparison, subtype denominators, or evidence on availability and patient outcomes.
October 23, 2026
Molecular Medicine
In a retrospective study of 1,254 exercise SPECT patients, the index added small but significant prognostic discrimination, mainly with low perfusion deficits. Overlap with heart-rate recovery and missing outcome data limit how far the findings reach.
October 22, 2026
Molecular Medicine
A feasibility study found heartbeat signals in most routine FDG PET scans without ECG leads, but ejection fraction limits of agreement were too wide for clinical interchange. Longitudinal testing in patients on chemotherapy has not been done.
October 15, 2026
Clinical Signals
A small rise in heart rate during regadenoson stress carries prognostic information. Turning that signal into a treatment decision remains a separate question.
October 12, 2026
Molecular Medicine
An early SPECT/CT study found encouraging agreement with surgery. Its small sample makes the reported accuracy a starting point for larger trials.
October 12, 2026
